A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer.

MLA

Jermusyk, Ashley, et al. “A 584 Bp Deletion in CTRB2 Inhibits Chymotrypsin B2 Activity and Secretion and Confers Risk of Pancreatic Cancer.” American Journal of Human Genetics, vol. 108, no. 10, Oct. 2021, pp. 1852–65. EBSCOhost, https://doi.org/10.1016/j.ajhg.2021.09.002.

APA

Jermusyk, A., Zhong, J., Connelly, K. E., Gordon, N., Perera, S., Abdolalizadeh, E., Zhang, T., O’Brien, A., Hoskins, J. W., Collins, I., Eiser, D., Yuan, C., Risch, H. A., Jacobs, E. J., Li, D., Du, M., Stolzenberg-Solomon, R. Z., Klein, A. P., Smith, J. P., … Amundadottir, L. T. (2021). A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. American Journal of Human Genetics, 108(10), 1852–1865. https://doi.org/10.1016/j.ajhg.2021.09.002

Chicago

Jermusyk, Ashley, Jun Zhong, Katelyn E Connelly, Naomi Gordon, Sumeth Perera, Ehssan Abdolalizadeh, Tongwu Zhang, et al. 2021. “A 584 Bp Deletion in CTRB2 Inhibits Chymotrypsin B2 Activity and Secretion and Confers Risk of Pancreatic Cancer.” American Journal of Human Genetics 108 (10): 1852–65. doi:10.1016/j.ajhg.2021.09.002.